SGMO

Sangamo Therapeutics, Inc.

1.11 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sangamo Therapeutics, Inc. stock is up 126.53% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 23 March’s closed higher than February. 100% of analysts rate it a buy.

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection.

  • HC Wainwright & Co.
    Mon Feb 12, 12:46
    buy
    confirm
  • HC Wainwright & Co.
    Tue Feb 6, 08:46
    buy
    confirm